Zetia Antitrust Litigation
Berger Montague represents a proposed class of direct purchasers of the drug Zetia (ezetimibe).
Plaintiffs allege that Merck & Co. Inc., Merck Sharp & Dohme Corp., Schering-Plough Corp., Schering Corp., MSP Singapore Co. LLC (collectively, “Merck”), Glenmark Pharmaceuticals LTD, and Glenmark Generics Inc. (together, “Glenmark”) entered into a reverse payment agreement that delayed generic competition to Merck’s brand cholesterol drug Zetia. The complaint alleges that this anticompetitive agreement caused plaintiffs to pay hundreds of millions in overcharges.
On February 6, 2019, U.S. Magistrate Judge Douglas E. Miller rejected Defendants’ motion to dismiss. On June 18, 2020, Judge Miller issued a report and recommendation recommending certification of the class of direct purchasers.
LEAD ATTORNEY: David F. Sorensen